Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Inter-Laboratory Assessment of Minimal Residual Disease In Chronic Lymphocytic Leukemia – Evaluation of the Novel CD160FCA Assay

Timothy Farren, BSc(HONS), MIBMS, Fengting Liu, MD, PhD, Claire Stephens, MSc, Marion Macey, PhD, FRCPath, Michael Jenner, MD, PhD, FRCPath, Archie Prentice, MB, FRCP, FRCPath, Amit Nathwani, MBChB, FRCP, FRCPath, Samir Agrawal, MD, PhD, FRCPath

Blood (2010) 116 (21): 2723.

https://doi.org/10.1182/blood.V116.21.2723.2723

Published: 2010

Journal Articles

Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells

Fengting Liu, MD, PhD, Li Jia, MD, PhD, Timothy Farren, BSc(HONS), MIBMS, John G. Gribben, MD, DSc, Samir Agrawal, MD, PhD

Blood (2010) 116 (21): 3598.

https://doi.org/10.1182/blood.V116.21.3598.3598

Published: 2010

Journal Articles

Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis.

Tom Butler, MBChB, FRCPath, Catherine Wiseman, BSc(Hons), MPhil, Timothy Farren, BSc(HONS), MIBMS, John G. Gribben, MD, DSc, Samir G Agrawal, MD, PhD

Blood (2009) 114 (22): 4371.

https://doi.org/10.1182/blood.V114.22.4371.4371

Published: 2009

Journal Articles

Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling.

Feng-Ting Liu, MB, PhD, Li Jia, MB, PhD, Timothy Farren, BSc(HONS), MIBMS, Jerome Giustiniani, Armand Bensussan, John G. Gribben, MD, DSc, Samir G Agrawal, MD, PhD

Blood (2009) 114 (22): 4372.

https://doi.org/10.1182/blood.V114.22.4372.4372

Published: 2009

Journal Articles

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Shankaranarayana Paneesha, MD, Aidan McManus, PhD, Roopen Arya, MBBS, PhD, Nicholas Scriven, MB, Tim Nokes, MD, Timothy Farren, BSc, Sue Bacon, SRN, Anthea Nieland, SRN, Denise O’Shaughnessy, MD, PhD, Peter Rose, MD

Blood (2008) 112 (11): 3826.

https://doi.org/10.1182/blood.V112.11.3826.3826

Published: 2008

Journal Articles

Using CD160 as a Novel Approach to the Assessment of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukaemia (CLL).

Timothy Farren, BSc (Hons), Jerome Giustiniani, PhD, Ulrika Johansson, PhD, Christina Lim, RN, Gemma Athorn, MSc, Adrian Newland, MD, Marion Macey, PhD, Samir Agrawal, MD, PhD

Blood (2007) 110 (11): 2036.

https://doi.org/10.1182/blood.V110.11.2036.2036

Published: 2007

Journal Articles

CLL Cell Proliferation and IL-6 Production Are Regulated by CD160 - MHC Class I Interactions Offering New Therapeutic Targets.

Jerome Giustiniani, PhD, Catherine Wiseman, BSc, Timothy Farren, BSc, John G. Gribben, MD, PhD, Samir G. Agrawal, MD, PhD

Blood (2007) 110 (11): 1126.

https://doi.org/10.1182/blood.V110.11.1126.1126

Published: 2007

NARROW

Inter-Laboratory Assessment of Minimal Residual Disease In Chronic Lymphocytic Leukemia – Evaluation of the Novel CD160FCA Assay

Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells

Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis.

Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling.

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Using CD160 as a Novel Approach to the Assessment of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukaemia (CLL).

CLL Cell Proliferation and IL-6 Production Are Regulated by CD160 - MHC Class I Interactions Offering New Therapeutic Targets.

Email alerts

ASH Publications

American Society of Hematology

Inter-Laboratory Assessment of Minimal Residual Disease In Chronic Lymphocytic Leukemia – Evaluation of the Novel CD160FCA Assay

Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells

Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis.

Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling.

Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study

Using CD160 as a Novel Approach to the Assessment of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukaemia (CLL).

CLL Cell Proliferation and IL-6 Production Are Regulated by CD160 - MHC Class I Interactions Offering New Therapeutic Targets.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only